Latest News – PSNC Main site
Pharmaceutical Services Negotiating Committee
Class 4 Drug Alert: Ibuprofen 400mg Tablets (Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd) – update
Drug alert number: EL (20)A/10 Date issued: 20 February 2020 – updated 24th February 2020 with further batches The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 pharmacy level caution in use for: Crescent Pharma Ltd, Flamingo Pharma (Uk) Ltd, Ibuprofen 400mg Tablets (Various Liveries) Crescent Pharma Ltd and Flamingo Pharma...
PQS: Declarations close on Friday, don’t miss the deadline!
Community pharmacy contractors only have until 11.59pm on Friday (28th February 2020) to submit their Pharmacy Quality Scheme (PQS). Declarations will not be accepted after this date; therefore, contractors will not be paid a PQS payment if they do not meet this deadline. Contractors must use the NHS Business Services Authority (NHSBSA) Manage Your Service portal to make their PQS declaration...
Contractor Announcement: CPCF Negotiations Progress Update and Arrangements for 2020/21
Announcement summary: The arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2020/21 have been agreed between PSNC, NHS England and NHS Improvement (NHSE&I) and the Department of Health and Social Care (DHSC), in line with the five-year CPCF deal. As set out in the deal, overall funding for community pharmacy will be set at...
CPCF in 2020/21 – Frequently Asked Questions
To accompany the announcement of arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2020/21, PSNC has set out responses to a number of questions to help to answer queries that community pharmacy contractors may have. PSNC Briefing 011/20: CPCF in 2020/21 – Frequently Asked Questions If you have any queries on this PSNC Briefing...
Community Pharmacy Funding in 2020/21
This briefing describes how community pharmacy funding will be distributed during 2020/21 and gives background information on how community pharmacy funding works. More briefings will follow as further details for funding in 2020/21 are agreed. PSNC Briefing 010/20: Community Pharmacy Funding in 2020/21 If you have any queries on this PSNC Briefing or you require...
February edition of CPN magazine is out
The February 2020 edition of PSNC’s Community Pharmacy News (CPN) is now available. This month’s CPN features: National audit determined; PSNC CEO Blog; PQS declaration period underway; and How to endorse instalment forms. View our CPN magazine online via the flipbook reader below or download the PDF copy. Please note, the colour PDF can be...
February 2020 Price Concessions – 2nd update
Department of Health and Social Care (DHSC) has today granted the following list of price concessions: Drug Pack size Price Concession Amiodarone 200mg tablets 28 £2.55 Desmopressin 200microgram tablets 30 £19.47 Lymecycline 408mg capsules 28 £6.50 Meloxicam 7.5mg tablets 30 £3.25 Mirtazapine 15mg tablets 28 £2.20 Mirtazapine 30mg tablets 28 £2.20 Mirtazapine 45mg tablets 28...
Supply Notification: H2-antagonists (Cimetidine, Famotidine and Nizatidine) – update
Update (20/02/2020): resupply dates now expected: Famotidine 20mg tablets are out of stock until the end of February 2020 (Tilomed) Mid March 2020 (Teva) Cimetidine 200mg tablets are out of stock until the end of March 2020 (Ennogen) May 2020 (Medley Pharma) Nizatidine 150mg and 300mg tablets: No confirmed resupply date (Medreich and Mylan) Department...
Shortage Notice: Salofalk (mesalazine) suppositories (500mg and 1g) – Update
Update (20/02/2020): resupply date now expected mid April 2020 for the 500mg suppositories, mid September 2020 for the 1g suppositories First published 24th October 2019 Dr Falk the sole supplier of the 500mg mesalazine suppository (Salofalk suppositories 500mg) has announced that they expect to be out of stock of this line until mid-December 2019. The...
Shortage Notice: Seroxat (paroxetine) 20mg/10ml oral solution – Update
Update (20/02/2020): resupply date now expected early March 2020 First published 25th October 2019 The Department of Health and Social Care (DHSC) have advised that paroxetine 20mg/10ml oral solution will be out of stock until January 2020 due to manufacturing delays. Paroxetine tablets remain available from various suppliers. Action required: For patients who do not...
PharmaTimes: PharmaTimes Website RSS
PharmaTimes - The latest news in healthcare and life sciences - PharmaTimes Website RSS
‘Record high’ two million people at type II diabetes risk
There are 1,969,610 people registered with a GP who have non-diabetic hyperglycaemia, a condition which puts people at high risk of type II.
New AI-created antibiotic can kill many antibiotic-resistant bacteria
The AI system can screen more than a hundred million chemical compounds in a matter of days.
NHS to install ‘LIGHT’ proton therapy
In addition to the launch, Advanced Oncotherapy will work with an NHS Trust on various research and development activities associated with the use of LIGHT to increase the awareness of proton therapy for the treatment of cancer.
Galderma’s investigational prurigo nodularis drug hits Phase II endpoint
Prurigo nodularis is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus.
Opdivo/Yervoy continues to impress in kidney cancer
The results represent the longest follow-up with any immuno-oncology–based therapy in previously untreated RCC patients.
GSK, Immatics team up for cancer cell therapies
Under the terms of the agreement, Immatics will receive an upfront payment of $45m.
NHS staff still face ‘unacceptable’ abuse from public
NHS leaders have confirmed that from April, NHS services will be able to protect staff by barring from non-emergency care any patient or visitor who inflicts discriminatory or harassing behaviour on staff.
Teva’s Austedo flunks in late-stage paediatric Tourette study
Compared to placebo, the drug didn’t achieve significant reduction in motor and phonic tics.
Half of GPs skip out ‘vital’ diabetes kidney test
The test, which is used to detect kidney damage that can lead to fatal complications, should be conducted every year.
Roche’s Tecentriq bags Priority Review in US
In a trial, the drug improved overall survival by 7.1 months compared with chemotherapy.
US breakthrough designation granted to Padcev in bladder cancer
The designation was granted based on results from the dose-escalation cohort and expansion cohort A of the EV-103 Phase Ib/II trial.
‘Transformative’ surgical robot trialled on NHS
The step marks a “pivotal milestone" for Versius.
New report highlights ‘toxic’ risk of propranolol
There was a 34% increase in overdose deaths caused by propranolol between 2012 and 2017, and by 2016 nearly 4.7 million prescriptions were issued to patients annually.
Opdivo, cabiralizumab combo falls short in pancreatic cancer
Bristol-Meyers Squibb said that it will continue to support the evaluation of cabiralizumab in select, ongoing investigator-sponsored trials.
Every sector of the pharmaceutical market is represented under one roof, this year in Madrid. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.
Find out more: https://www.cphi.com/europe/